Vicuron Pharmaceuticals: Clinical Trials

4 completed, 1 unknown. 5 Phase 2, 1 Phase 1, 1 Phase 3.

By phase and status

Phase	Trials	Status
Phase 2	5	Completed 4, Unknown 1
Phase 1	1	Completed 1
Phase 3	1	Completed 1

Follow Vicuron Pharmaceuticals: new trials by email

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Safety, Tolerance and Pharmacokinetics of Anidulafungin in Immunocompromised Children Ages 2-17 Anidulafungin - Neutropenia	Phase 1 / Phase 2	Completed	Pfizer	25	2003-07-01	2008-10-21
The Safety and Efficacy of Intravenous Anidulafungin as a Treatment for Azole-Refractory Mucosal Candidiasis (FRMC) Anidulafungin, VER002 - Candidiasis	Phase 2	Completed	Pfizer	19	2002-08-01	2008-10-20
A Safety & Effectiveness Study of Intravenous Anidulafungin With AmBisome® for Treatment of Invasive Aspergillosis (IA). Anidulafungin, VER002 - Aspergillosis	Phase 2 / Phase 3	Completed	Pfizer	30	2002-05-01	2008-10-21
The Safety and Effectiveness of Intravenous Anidulafungin as a Treatment for Patients With Invasive Candidiasis. Anidulafungin, VER002 - Candidiasis	Phase 2	Completed	Pfizer	120	2001-08-01	2008-10-21
Safety and Efficacy of Dalbavancin Versus Vancomycin in the Treatment of Catheter-Related Bloodstream Infections dalbavancin - Bacteremia	Phase 2	Unknown	Vicuron Pharmaceuticals	88	2001-02-01	2005-06-24

Conditions studied

Candidiasis (2)  ·  Aspergillosis (1)  ·  Bacteremia (1)  ·  Candidemia (1)  ·  Candidiasis, Invasive (1)  ·  Febrile Neutropenia (1)  ·  Fever (1)  ·  Neutropenia (1)

Interventions

Anidulafungin (4)  ·  dalbavancin (1)

Countries

United States (5)

Results publications

PMID 34905144